### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

# INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56, §1.97, AND §1.98

## PTO-1449 FORM (MODIFIED)

SHEET 1 OF 1

ATTORNEY DOCKET NO. PP20426.003	SERIAL NO. 10/814,480
APPLICANTS: Nicholas M. Valiante	EXAMINER: Yong Soo
FILING DATE: March 29, 2004	
CONFIRMATION NO.	GROUP ART UNIT:

and the second	ENT DOCUM						
Ex'r in itial	Ref. No.	Document No.	Date	Name	Class	Subclass	Filed
Yc	A1	6,211,177	3 April 2001	Speri et al.			
	A2	6,248,771	19 June 2001	Shenoy et al.			
	A3	6,399,603	4 June 2002	Jacobs et al.			
1	A4	6,417,194	9 July 2002	Fox et al.			

e tempo de la companiona de la companion			FOREIGN PATENT DO	CUMENTS			
Exir I nitial	Ref. No.	Document No.	Publication Date	Country	Class	Subclass (	, Translation YES NO
YC	B1	WO 00/62778 A	26 October 2000	PCT			
i i	B2	WO 01/66539 A	13 September 2001	PCT			
	В3	W004/985425A1	7 October 2004	PCT			
	B4	W002/42273A2	30 May 2002	PCT			
	B5	W002/44156A2	6 June 2002	PCT			
	В6	W002/076960A1	3 October 2002	PCT			
	В7	W002/094808A1	28 November 2002	PCT			
Ų.	88	W003/082272A1	9 October 2003	PCT			

	<b>0</b> 1	THER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
Ex'r n itial	Ref. No.	Description!
YC	C1	
	C2	
	C3	
₩	C4	

EXAMINER'S SIGNATURE  Jong Chong	DATE CONSIDERED

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609.

Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.

If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to
the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R.
1.98(d).

SHEET	1	OP	1

FORM PTO-1449 (MGF1fied)	U.S. Dept. of Commerce Patent and Trademark Office	Atty. Docket No.: 20426.003	Serial No.: 10/814,480
INFORMATION DISCL	OSURE CITATION	Applicants: Valiante et al.	
(Use several s	heets if necessary)	Filing Date: March 29, 2004	Group: 1617

#### U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Piling Date If Appropriate
YL	AA	2002/0107392	08/08/02	Renhowe <u>et</u> <u>al</u> .	544	60	09/11/01
<del></del>							
····							
						<u></u>	
			1				

#### FOREIGN PATENT DOCUMENTS

		Document Number	Publ. Date	Country	Class	Subclass	Trans- Yes	lation No
YC	ВА	WO 92/18483	10/29/92	PCT				
1	ВВ	WO 03/074515 A1	09/12/03	PCT				
	ВС	WO 03/082272	10/09/03	PCT				
	BD	WO 2004/018419 A2	03/04/04	PCT				
V	BE	WO 2004/085425 A1	10/07/04	PCT				
	İ							

OTHER CITATIONS (Including Author, Title, Date, Pertinent Pages, Etc.)

		OTHER CHAILORS (Including Author, Title, Date, Fertinent Pages, Etc.)
YC.	CA	Ukrainets et al., "4-Hydroxy-2-Quinolones. 32. Synthesis and Antithyroid Activity of Thio Analogs of 1H-2-Oxo-3-(2-Benzimidazoly1)-4-Hydroxyquinoline" Chemistry of Heterocyclic Compounds 33(5):600-604, 1997
Yc	СВ	Ukrainets et al., "4-Hydroxy-2-Quinolones 7 Synthesis and Biological Properties of 1-R-3-(2-Benzimidazolyl)-4-Hydroxy-2-Quinolones" Chemistry of Heterocyclic Compounds 29(1):92-94, 1993
		<del></del>
<b></b>		

Examiner 7	Date Considered /0/20/05	
Jory Mary	10/20/03	

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<u> </u>			
FORM PTO-1449 Modified)	U.S. Dept. of Commerce Patent and Trademark Office	Atty. Docket No.: 20426.003	Serial No.: 10/814,480
INFORMATION DISCL	OSURE CITATION	Applicants: Valiante et al.	
(Use several s	heets if necessary)	Filing Date: March 29, 2004	Group: to be assigned

U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
YL	AA	2002/0022624	02/21/02	Dinnell <u>et al</u> .			

#### FOREIGN PATENT DOCUMENTS Publ. Class Subclass Translation Document Number Country Date WO 00/12074 03/09/00 PCT YC 03/21/02 PCT ВВ WO 02/22598 WO 00/76505 12/21/00 PCT (abstract only) BD WO 01/64668 09/07/01 PCT 05/02/01 BE WO 02/090375 PCT BP WO 02/083624 10/24/02 PCT ВG WO 03/000694 01/03/03 PCT вн WO 00/59904 10/12/00 PCT

		OTHER CITATIONS (Including Author, Title, Date, Pertinent Pages, Etc.)				
YC	AA	Sato et al., "Characteristics of Antitumor Activity of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl)" Cancer Letters 91:1-9, 1995				
	AB	Oyaizu et al., "Inhibition of CD4 Cross-Linking-Induced Lymphoyetes Apoptosis by Vesnarinone as a Novel Immunomodulating Agent " <u>Blood</u> 87(6):2361-2368, March 15, 1996				
	AC	Toldy et al., "3,4,5-Trimethoxybenzoylderivative, Eine Neue Verbindungsgruppe Mit Antiulzerogener Wirkung" <u>Acta Chimica Academiae Scientiarum Hungaricae Tomus 49</u> (3):265- 286, 1966				
	AD	Sato et al., "Induction of Tumour Differentiation and Apoptosis and Le <sup>T</sup> Antigen Expression in Treatment with Differentation-Inducing Agent, Vesnarinone, of a Patient with Salivary Adenoid Cystic Carcinoma" Apoptosis 2:106-113, 1997				
	AE	Petigara et al., "Synthesis and Central Nervous System Depressant Activity of New Piperazine Derivatives" 11:332-336, March 1, 1968				
4	AF	Yamaguchi, "Vesnarinone Inhibits Growth of Large Cell Lung Cancer Cell Lines via Induction of Apoptosis" Med. J. Kagoshima Univ. 51(4):67-75, Pebruary, 2000				
		·				
Examiner	Zfor	y Chory Date Considered 10/20/05				
<del></del>	- 77 - 7					

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.